Skip to main content

Table 3 MENQOL scores based on the four domains among studied patients

From: Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors

 

vasomotor domain

psychosocial domain

physical domain

sexual domain

Mean score

SD

p

Mean score

SD

p

Mean score

SD

p

Mean score

SD

p

Overall population

2.51

1.70

–

2.76

1.41

–

2.82

1.10

–

2.61

1.90

–

No. of patients with scores >/= mean (%)

103 (36.8)

  

119 (42.5)

  

130 (46.4)

  

107 (38.2)

  

Age at time of study entry

  

0.1227

  

0.1036

  

0.6317

  

0.2397

  ≤ 40

2.25

1.69

 

2.28

1.13

 

2.73

1.14

 

1.99

1.53

 

 41–45

2.46

1.73

 

2.93

1.51

 

2.95

1.20

 

2.65

1.84

 

 46–50

2.70

1.75

 

2.81

1.41

 

2.78

1.03

 

2.70

2.02

 

  > 50

1.90

1.01

 

2.48

1.34

 

2.74

1.13

 

2.81

1.70

 

BMI at study entry

  

0.8753

  

0.3717

  

0.0162

  

0.2760

 Underweight or Normal

2.53

1.73

 

2.68

1.37

 

2.65

1.07

 

2.74

1.93

 

 Overweight or Obese

2.50

1.67

 

2.83

1.44

 

2.97

1.11

 

2.49

1.87

 

Breast surgery:

  

0.9321

  

0.6877

  

0.5563

  

0.1375

 Lumpectomy

2.52

1.69

 

2.71

1.42

 

2.76

1.05

 

2.37

1.64

 

 Mastectomy

2.50

1.70

 

2.78

1.41

 

2.84

1.13

 

2.73

2.01

 

Axillary nodal dissection

  

0.6127

  

0.3630

  

0.7797

  

0.1500

 Yes

2.52

1.70

 

2.75

1.41

 

2.81

1.10

 

2.63

1.90

 

 No

2.08

1.95

 

3.39

0.88

 

2.97

0.61

 

1.25

0.50

 

Adjuvant radiotherapy

  

0.7467

  

0.3781

  

0.7246

  

0.9861

 Yes

2.53

1.58

 

2.70

1.36

 

2.83

1.05

 

2.61

1.87

 

 No

2.46

1.76

 

2.86

1.50

 

2.78

1.18

 

2.61

0.50

 

Adjuvant chemotherapy regimen:

  

0.0140

  

0.9373

  

0.7131

  

0.9094

 Taxane-containing

2.91

1.89

 

2.75

1.26

 

2.85

1.02

 

2.59

1.84

 

 Non-taxane-containing

2.35

1.59

 

2.76

1.46

 

2.80

1.13

 

2.62

1.92

 

Duration of adjuvant chemotherapy

  

0.2232

  

0.3966

  

0.8625

  

0.8946

  < =64 days

2.33

1.75

 

2.86

1.51

 

2.80

1.14

 

2.63

2.09

 

  > 64 days

2.60

1.57

 

2.71

1.36

 

2.82

1.08

 

2.60

1.80

 

Time since last adjuvant treatment*

  

0.2568

  

0.4249

  

0.3966

  

0.3051

 3 to < 5 years

2.61

1.69

 

2.70

1.36

 

2.77

1.08

 

2.51

1.85

 

 5 to < 10 years

2.38

1.70

 

2.83

1.47

 

2.88

1.13

 

2.74

1.96

 

Ever received adjuvant tamoxifen

  

0.8659

  

0.8076

  

0.8320

  

0.7338

 Yes

2.52

1.76

 

2.77

1.38

 

2.82

1.12

 

2.59

1.88

 

 No

2.48

1.50

 

2.72

1.52

 

2.79

1.03

 

2.68

1.98

 

On adjuvant tamoxifen at study entry

  

0.0479

  

0.7057

  

0.9349

  

0.6175

 Yes

2.75

1.84

 

2.79

1.32

 

2.82

1.10

 

2.54

1.86

 

 No

2.34

1.57

 

2.73

1.47

 

2.81

1.10

 

2.65

1.93

 

Adjuvant targeted therapy with trastuzumab

  

0.7117

  

0.8083

  

0.9443

  

0.7262

 Yes

2.29

1.20

 

2.88

1.56

 

2.79

0.72

 

2.38

1.86

 

 No

2.52

1.71

 

2.75

1.41

 

2.82

1.11

 

2.61

1.90

 

Utilization of traditional Chinese medicine since diagnosis

  

0.0054

  

0.0028

  

0.0052

  

0.3732

 Yes

2.94

1.80

 

3.14

1.55

 

3.10

1.19

 

2.76

1.95

 

 No

2.33

1.62

 

2.59

1.31

 

2.70

1.04

 

2.54

1.88

 

Menopausal status at study entry

  

0.2079

  

0.7446

  

0.9338

  

0.0229

 Premenopausal

2.35

1.67

 

2.72

1.49

 

2.82

1.16

 

2.29

1.64

 

 Peri/Post- menopausal

2.62

1.71

 

2.78

1.35

 

2.81

1.06

 

2.82

2.03

 
  1. *Only include chemotherapy/radiotherapy or trastuzumab
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us